Q-omics provides the consensus-scored CRYGFP profile across patient tissues and cancer cell-line models. CRYGFP expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CRYGFP is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, CRYGFP RNA expression shows 7,292 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, LUSC, and TGCT as cancer lineages where CRYGFP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYGFP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYGFP survival associations across molecular data types. CRYGFP RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYGFP RNA expression–survival associations across cancer types. High CRYGFP expression shows unfavorable associations in LIHC, ESCA, COAD, MESO, LUSC and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CRYGFP RNA expression.
This table summarizes CRYGFP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CRYGFP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYGFP shows higher tumor expression in LUSC. The LUSC box plot shows higher CRYGFP RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .046).
This table shows molecular features associated with CRYGFP in patient tissues and cancer cell lines. In patient samples, CRYGFP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
